|
|
|
|
|
|
|
|
|
|
|
03.03.26 - 14:06
|
Kivu Bioscience Appoints Brunilda Shtylla as Chief Business Officer (Business Wire)
|
|
|
Seasoned biopharma executive brings more than 25 years of business development and strategic partnership experience to support Kivu's next phase of growthSAN MATEO, Calif.--(BUSINESS WIRE)--#ADC--Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced the appointment of Brunilda Shtylla, as Chief Business Officer. Ms. Shtylla will lead corporate strategy, business development, and partnership initiatives as the company advances its ADC pipeline in clinical development and expands its strategic collaborations.
Ms. Shtylla brings more than 25 years of experience across biotechnology, medical devices, finance, and strategic transactions. Most recently, as Chief Business Officer at Sutro Biopharma, she led business strategy and development, advancing the company's platform through collaborations, licensing, and partnerships, and helping secure more than $5.5 billion in total deal value. Previously, she...
|
|
|
25.02.26 - 14:33
|
Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences....
|
|
|
|
|
|
|
10.02.26 - 13:03
|
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions....
|
|
|
|
|
07.01.26 - 22:09
|
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:15 AM PT / 2:15 PM ET in San Francisco, CA. ...
|
|
|
10.12.25 - 09:39
|
XFRA: S090: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
SUTRO BIOPHARMA NEW O.N. S090 US8693672011
AB/FROM ONWARDS 10.12.2025 08:11 CET...
|
|
|
03.12.25 - 08:57
|
XFRA: S090: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
SUTRO BIOPHARMA NEW O.N. S090 US8693672011 BAW/UFN...
|
|
|
|
|
02.12.25 - 17:18
|
XFRA: ISIN Change (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
CA83410N1096 Sokoman Minerals Corp. 02.12.2025 CA7242551041 Pirate Gold Corp. 03.12.2025 Tausch 1:1
AU0000274284 Tusker Minerals Ltd. 02.12.2025 AU0000437634 Tusker Minerals Ltd. 03.12.2025 Tausch 1:1
AU0000272072 Ore Resources Ltd. 02.12.2025 AU0000436933 Ore Resources Ltd. 03.12.2025 Tausch 1:1
CA89626F1036 United Critical Minerals Corp. 02.12.2025 CA91016A1084 United Critical Minerals Corp. 03.12.2025 Tausch 1:1
US8693671021 Sutro Biopharma Inc. 02.12.2025 US8693672011 Sutro Biopharma Inc. 03.12.2025 Tausch 10:1...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
